SMITHKLINE RETURNING TO HMG-CoA MARKET WITH BAYCOL CO-PROMOTION AGREEMENT; LAUNCH WITH BAYER SET FOR EARLY 1998: PAXIL SALES INCREASE 33% FOR QUARTER
Executive Summary
SmithKline Beecham will re-enter the HMG-CoA reductase inhibitor market via a co-promotion agreement with Bayer for the launch of Baycol (cerivastatin).